Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a small molecule heterocyclic organic compound with the formula C10H14N2OS. It is classified as an alkyl aryl ether and features a thienoxazepine core structure. The molecule has been studied in structural biology contexts and is known to bind to the oxygenase domain of human endothelial nitric oxide synthase (eNOS/NOS3), acting as an inhibitor in crystallographic studies. Its primary use appears to be experimental and research-based rather than clinical or therapeutic at this time. No approved medical indications or marketed formulations are reported for this compound[1][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (3S,5E)-3-propyl-3,4-dihydrothieno[2,3-f][1,4]oxazepin-5(2H)-imine.